Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Briumvi, ublituximab-xiiy
Synonyms :
ublituximab
Class :
Neurologic, monoclonal antibody
Brand Name :
Briumvi, ublituximab-xiiy
Synonyms :
ublituximab
Class :
Neurologic, monoclonal antibody
Dosage Forms & StrengthsÂ
Injectable solutionÂ
25mg/mlÂ
First infusion:150 mg intravenous
Second infusion: After two weeks of the first infusion, administer 450mg intravenous
Further infusions: After 24 weeks of the first infusion, administer 450mg intravenous
Dosage Forms & StrengthsÂ
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
It may enhance the immunosuppressive effects when combined with risankizumab
atoltivimab/maftivimab/odesivimabÂ
atoltivimab/maftivimab/odesivimab and ublituximab together reduce immunosuppressive effects
It may enhance the effects when combined with triamcinolone by immunosuppressive effects
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
may decrease the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
It may enhance the adverse effects when combined with sotrovimab
may increase the immunosuppressive effect of Immunosuppressants
the risk of infection can be raised if ublituximab is taken with fluocortolone
Frequency defined:Â Â
>10%Â
Upper respiratory tract infectionsÂ
Reactions at the infusion siteÂ
1-10%Â
Infections associated with the herpes virusÂ
Extremity painÂ
FatigueÂ
Lower respiratory tract infectionsÂ
InsomniaÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: ublituximabÂ
Pronounced: (ue” bli tux’ i mab)Â
Why do we use ublituximab?Â
ublituximab (also known as Briumvi) is a monoclonal antibody being investigated for its potential use in treating multiple sclerosis (MS). It is designed to target a specific protein called CD20 found on certain immune cells’ surfaces called B cells. In people with MS, B cells are thought to play a role in the immune system’s attack on the protective coating (called myelin) surrounding nerve fibers in the brain and spinal cord.
By targeting CD20, ublituximab may help to reduce the number of B cells in the body and potentially reduce inflammation and nerve damage in people with MS. However, ublituximab is still being investigated in clinical trials, and regulatory agencies have not yet approved it for use in the treatment of MS or any other condition.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
